Kornimate/medical-research-clean huggingface dataset:
multiple sclerosis in the elderly: epidemiology, clinical and mri characteristics

Conditions: Multiple Sclerosis

Summary: little is known about old ms patients. in a previous work, systematic search in bordeaux, strasbourg and dijon university hospital regional ms center databases european database for multiple sclerosis (edmus) retrieved 2% of 75 years old or older multiple sclerosis (ms) patients in the 3 databases. data analysis showed that ms may switch off in the very old patients with mild progression and very few relapses. the project is to continue this preliminary work and extend it with a systematic study of ms in the elderly. the scientific aims: to add new insights into long lasting ms natural history in the growing population of elderly patients with ms.

75 to 77 years old ms patients whose disease began at 65 years old or earlier will be retrieved from the "observatoire français de la sclérose en plaques" (ofsep) which includes more than 50 000 ms patients in france. accuracy of these patients' data from 65 to 75 years old will be thereafter checked and completed in 3 french ms centers: lyon, rennes and bordeaux, participating to this database directly from the patients' clinical files. from these 3 ms centers around 150 ms patients from 75 to 77 years old are expected to be analysed on site. the data wich will be retrieved for these patients are: irreversible disability status scale progression, relapses, magnetic resonance imaging (mri) data, csf data, lublin classification of type of ms, mcdonald 2005 and 2010 criteria, date and age at beginning of progression, characteristics and modality of relapses and clinical impairment at the beginning of the disease, treatments used, treatment failures and side effects, co morbidity, barthel index, euroqol-5d (eq-5d), cognitive impairment (sdmt test), social life data and socio economic data. to the investigator's knowledge this will be the first systematic description of very old ms patients with data on long term natural history of ms and characteristics in this population of elderly ms patients.

Eligibility criteria:
inclusion criteria: * patients with mcdonald 2001, 2005 or 2010 criteria of multiple sclerosis 75 to 77 years old ms patients at the time of inclusion * patients whose beginning of ms was before 65 years old or 65 years old * patients who signed ofsep 's consent exclusion criteria: * patients whose clinical data cannot be entered or for whom too much clinical data are missing * alive patients older than 77 years or younger than 75 years the day of the inclusion in the study * patients died before 65 years old

Keywords: geriatric population edmus ofsep
long term follow-up of integra® cadence™ total ankle system in primary ankle joint replacement

Conditions: Degenerative Arthritis; Rheumatoid Arthritis; Traumatic Arthritis

Summary: this study will evaluate the long term performance and safety data for the cadence™ total ankle system (ctas) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)


Eligibility criteria:
inclusion criteria: subjects will be included if he/she: * qualifies for primary total ankle replacement (tar) per the surgeon and has a diagnosis of one of the following: primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), or systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis). * is suitable for tar with cadence™ total ankle system per the study surgeon based on the product indication and having considered deformity, stability, bone quality, soft- tissue envelope, and neurovascular status. * is willing and able to complete scheduled follow-up visits, evaluations and questionnaires as described in the informed consent (or information letter and data transfer authorization form, as applicable). exclusion criteria: subjects will be excluded from the study if he/she: * is morbidly obese (defined by a body mass index (bmi) \> 40 or bmi of 35 - 40 with significant medical problems caused by or made worse by their weight). * has one of the following conditions, which could compromise the affected limb: ankle arthrodesis with malleolar exeresis, severe neurological (charcot's arthropathy) or vascular disease, loss of musculature or neuromuscular compromise. * has an active local/systemic infection that may affect the prosthetic joint or has a recent history of infection. * has a condition that may impair proper wound healing (e.g., poor soft tissue envelope). * has a metabolic disorder or disease that may compromise bone quality (e.g. arthrogryposis etc.), physiological or anatomical anomalies, and/or malignancy/local bone tumors. * has inadequate neuromuscular status (e.g., prior paralysis, severe neuropathy). * has a known sensitivity or allergic reaction to one or more of the implanted materials.
imaging biomarkers in preclinical and symptomatic ad

Conditions: Alzheimer Disease

Summary: the purpose of this research study is to evaluate adult children of parents with and without alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of ad. the investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). amyloid is a protein that may be related to dementia of alzheimer's disease (dat).

this study will use a radioactive tracer called \[11c\]-pittsburgh compound b (11c\]pib), which is a tracer that binds to beta amyloid protein in the brain. this compound is considered investigational, which means that it has not been approved by the united states food and drug administration (fda).

Eligibility criteria:
inclusion criteria: * male or female, any race; * age ≥ 18 years; * active participants currently enrolled in the knight alzheimer's disease research center (adrc) at washington university. exclusion criteria: * hypersensitivity to \[11c\] pib or any of its excipients; * contraindications to pet, ct or mri (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate; * severe claustrophobia; * women who are pregnant or breast-feeding will be excluded from pib pet participation; * has any condition that, in the opinion of the sponsor-investigator or designee could increase risk to the subject, limit the subject's ability to tolerate the research procedures, or interfere with collection of the data; * currently participating in any clinical trial which involves an active study medication or placebo within the past 30 days before scanning and up to 2-weeks past the imaging visit. * current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the u.s. code of federal regulations (cfr) title 21 section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=361.1

Keywords: alzheimer's disease neurology radiology nuclear medicine
a study of neorecormon in patients with chronic kidney disease.

Conditions: Anemia

Summary: this 2 arm study will compare the level of anemia, and the decline in renal function, between patients receiving neorecormon, and those not receiving it. patients with chronic kidney disease, stage 2-4, and not receiving dialysis, will be randomized 2:1 to a group receiving neorecormon (at a dose determined by the investigator to achieve and maintain an hb level of 120-135 g/l), or to a control group not receiving neorecormon. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients,18-75 years of age; * end-stage renal disease, not on dialysis; * hb \<110g/l. exclusion criteria: * unstable hypertension; * acute infections; * use of i.v. neorecormon, or use of any other esa beside neorecormon; * myocardial infarction, unstable angina or venous thrombosis within 6 months before start of treatment.
testing the elevation as sleep apnea treatment

Conditions: Sleep Apnea, Obstructive; Sleep Apnea Syndromes; Sleep

Summary: the purpose of this study is to determine if the elevation of the head of the bed in patients with obstructive sleep apnea can decrease the apnea-hypopnea index. first the investigators will do a standard polysomnography and see if the patients are included analysing the criteria like apnea-hypopnea index equal or more than 5. within 2 weeks the patient will do the second polysomnography but this will be with a elevation of the head of the bed (15 cm of elevation of the bed doing a inclination). then the investigators will compare the data of apnea-hypopnea index in the standard polysomnography versus the index with the elevation of the head of the bed.

there are many researches that demonstrate that the position of the patient modified the apnea-hypopnea index(iah). in supine position the iah will increase comparing with lateral position during th sleep. however few studies were done with the elevation of the head of the bed. first the investigators will do a standard polysomnography and see if the patients are included analysing the criteria like apnea-hypopnea index equal or more than 5. within 2 weeks the patient will do the second polysomnography but this will be with a elevation of the head of the bed (15 cm of elevation of the bed doing a inclination). then the investigators will compare the data of apnea-hypopnea index in the standard polysomnography versus the index with the elevation of the head of the bed.the main outcome will be to analyze the apnea hypopnea index comparing standard polysomnography (spsg) with elevated polysomnography (epsg).

Eligibility criteria:
inclusion criteria: * berlin questionnaire high risk * epworth score \> 9 * obstructive sleep apnea with an index ≥ 5 events/hour on the polysomnography (the american academy of sleep medicine manual for the scoring of sleep and associated events: rules,terminology and technical specifications. american academy of sleep medicine, 2012) exclusion criteria: * younger than 18 years and older than 80 years * bmi more than 40 kg/m2 * heart failure * renal failure * uncontrolled respiratory disease * uncontrolled neurological disease

Keywords: sleep apnea, obstructive sleep apnea syndromes polysomnography sleep patient positioning
european database on catheter-directed treatment of pulmonary embolism.

Conditions: Acute Pulmonary Embolism

Summary: the main goals of europe-cdt is to assess the currently applied catheter-directed treatment (ctd) techniques and strategies in pulmonary embolism (pe) patients and to determine the short term efficacy and safety of this invasive procedure.

this is a prospective (and retrospective, if required data are available), non-interventional, multicenter study. we intend to obtain data on basic patients characteristics, pulmonary embolism severity, catheter-directed treatment procedures and short term outcome. we are planning to include approximately 150-200 patients suitable for analysis by the end of 2020. anonymized data of consecutive pe patients treated with ctd in european centers will be collected in the database.

Eligibility criteria:
inclusion criteria: * acute pulmonary embolism * catheter-directed embolectomy exclusion criteria: * appropriate data not available
patient-ventilator dyssynchrony detection with a machine learning algorithm

Conditions: Respiratory Failure

Summary: this is a diagnostic study aiming to compare accuracy to detect and classify patient-ventilator dyssynchronies by a machine learning algorithm, compared to the gold-standard defined as dyssynchronies diagnosed and classified by mechanical ventilator and esophageal pressure waveforms analyzed by experts. the main question of this study is: • are patient-ventilator dyssynchronies accurately detected and classified by an artificial intelligence algorithm when compared to experts analyzing esophageal pressure and mechanical ventilator waveforms?

this is a diagnostic, observational study, aiming to assess patient-ventilator dyssynchrony automated detection and classification by a machine learning algorithm. accuracy of the machine learning algorithm will be compared with the gold-standard, defined as dyssynchronies detected and classified by mechanical ventilation experts. experts will analyzed airway pressure, flow, volume and esophageal pressure waveforms to detect and classify dyssynchronies.

Eligibility criteria:
inclusion criteria: * subjects under assisted or assist-controlled mechanical ventilation and monitored with esophageal pressure balloon. exclusion criteria: * refusal from patient's family or attending physician

Keywords: mechanical ventilation artificial intelligence
chest physical therapy on arterial blood gases for neonates post hypoxic ischemic encephalopathy

Conditions: Hypoxic Ischemic Encephalopathy of Newborn

Summary: hypoxic-ischemic encephalopathy (hie) is a dangerous illness that happens when a newborn's brain does not receive adequate oxygen and blood flow, which can result in serious effects such as cerebral palsy and epilepsy. infant diagnosed with hie required ventilator support and subsequently developed pneumonia. they experienced respiratory problems and feeding challenges. chest physical therapy is the best modalities to clear chest and improve ventilation.

the purpose of this study to investigate the effect of chest physical therapy on arterial blood gases for neonates post hypoxic ischemic encephalopathy (hie) in neonatal intensive care unit. methods: fifty neonates from both sexes, age from birth to 10 days, post hie with chest problems were selected from neonatal intensive care unit (nicu) at minia university hospital, egypt. they were divided into two equal groups, control group (cg) received traditional medical treatment according to american academy of pediatrics (aap) recommendations and study group (sg) received traditional medical treatment plus chest physical therapy (cpt) modalities in the form of postural drainage, percussion and vibration. the sessions will apply once daily for 6 days/week, each session is about 30 minutes, according to the neonate tolerance till complete clinical cure and discharge from nicu. the outcome will measure by timing of arterial blood gases improvement, duration required for clinical improvement, duration of mechanical ventilation, duration of hospitalization.

Eligibility criteria:
inclusion criteria: * neonates with chest problems post hypoxic-ischemic encephalopathy exclusion criteria: * neonates with chest problems due to other causes except post hypoxic-ischemic encephalopathy. * unstable medical status * neonates with post-operative s' respiratory problems due to any reasons.
anterior wedge in patients with osteoarthritis hip

Conditions: Gait, Frontal

Summary: ostearthritis is a great source of pain. in symptomatic hip the pain can lead the major disability and poor quality of life. understand the musculoskeletal factores can lead to a better clinical management. the muscle strenghening of posterolateral complexo of hip is a important consideration. general objective: perform a kinetic analysis 2d using na anterior wedge. specific objective: analyze the influence of posterolateral hip complex. controlled clinical trial, composed by 30 individuals with and without osteoarthritis of hip e will be used a tools; analogic visual scale, manual dynamometry to analyze force and kinetic analyze of gait through of myovídeo analysis software.


Eligibility criteria:
inclusion criteria: * sedentary individuals * both genders * age equal to or greather than 50 years * diagnosis of osteoarthritis level ii and iii exclusion criteria: * fractures * neuromuscular diseases * other diseases of hip
study of an intervention to improve problem list accuracy and use

Conditions: Attention Deficit Disorder With Hyperactivity; Asthma; COPD; Breast Cancer; Coronary Artery Disease; Congestive Heart Failure; Diabetes; Glaucoma; Hemophilia; Hypertension; Hyperthyroidism; Hypothyroidism; Myasthenia Gravis; Osteoporosis; Osteopenia; Renal Failure; Renal Insufficiency; Sickle Cell Disease; Stroke

Summary: the aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians the opportunity to correct them. the investigators will randomize the clinics that will receive the intervention and formally evaluate the study after a period of 6 months for improved problem list completeness to determine the effectiveness of our intervention.

the clinical problem list is a cornerstone of the problem-oriented medical record. problem lists are used in a variety of ways throughout the process of clinical care. in addition to its use by clinicians, the problem list is also critical for decision support and quality measurement. patients with gaps in their problem list face significant risks. for example, if a hypothetical patient has diabetes properly documented, his clinician would receive appropriate alerts and reminders to guide care. additionally, the patient might be included in special care management programs and the quality of care provided to him would be measured and tracked. without diabetes on his problem list, he might receive none of these benefits. in this study, the investigators developed an clinical decision support intervention that will identify patients with problem lists gaps. the investigators will alert providers of these likely gaps and offer providers the opportunity to correct them.

Eligibility criteria:
inclusion criteria: * independent healthcare provider (physician, np, pa) * practices at participating site exclusion criteria: * none
the effect of a brief intervention on anthropometric and metabolic variables

Conditions: Brief Intervention

Summary: this study will evaluate the effect of a brief intervention on anthropometric and metabolic changes in overweight women with low health literacy. the total number of samples was determined as 88. it was decided to recruit a total of 124 people, 62 people in each group, with a 40% loss in the groups. brief intervention interviews will be conducted with the intervention group. brief intervention interviews will take an average of 20-30 minutes and four times. the control group will not be intervened except for the first and last evaluations.

this study will evaluate the effect of a brief intervention on anthropometric and metabolic changes in overweight women with low health literacy. the total number of samples was determined as 88, 44 in each of the intervention and control groups. it was decided to recruit a total of 124 people, 62 people in each group, with a 40% loss in the groups. randomization will be performed after obtaining consent from the participants who meet the eligibility and exclusion criteria. the sampled individuals will be assigned to the intervention and control groups according to the block randomization method. brief intervention interviews will be conducted with the intervention group. it was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). brief interventions, 5a for those who are ready to change their behavior (ask, advise, assess, assist, arrange); those who are not ready to change their behavior 5r (relevance, risks, rewards, roadblocks, repetition) model will be used. at the end of brief interventions applied to overweight women with low health literacy for 20-30 minutes, a total of four times; weight change, waist circumference change, blood pressure change, blood glucose change, blood lipid change, diet, and exercise behaviors will be evaluated. the control group will not be intervened except for the first and last evaluations.

Eligibility criteria:
inclusion criteria: * having heart disease, stroke, and chronic kidney failure diagnosed by a physician, * having diabetes that requires the use of insulin, * having hypothyroidism that prevents weight loss, * participating in a weight management program in the last 3 months, * being diagnosed with a disease that causes deterioration in cognitive processes such as alzheimer's and dementia, * having a diagnosed physical or neurological problem that prevents him from doing physical activity, * people who plan to become pregnant or become pregnant during the trial period (8 months after enrollment in the trial) exclusion criteria: * between 12.09.2023 and 24.06.2024 two primary healthcare organization applied, * volunteered to participate in the research, * women between the ages of 30-65, * the level of health literacy is limited-restricted, * 25≥ bmi \< 30, * those who can read and understand turkish will be included in the study.

Keywords: brief intervention overweight health literacy weight change metabolic variables
next dpi laba, multicentre, 5-way cross-over, adult asthmatic patients

Conditions: Asthma

Summary: multinational, multicentre, randomised, double blind, double dummy, placebo and active controlled, 5-way cross over

to demonstrate the non-inferiority in terms of fev1 auc0-12h between a single dose of chf 1535 via next dpi and chf 1535 via hfa-134a "extrafine" pmdi in partly controlled adult asthmatic patients

Eligibility criteria:
inclusion criteria: * patient's written informed consent obtained prior to any study-related procedures. * outpatient male or female aged ≥ 18 years. * evidence for "partly controlled" asthma in the 2 weeks before the screening visit * under previous inhaled corticosteroids (ics) treatment at the screening visit * forced expiratory volume in the first second (fev1) ≥ 60% and ≤ 90% of the predicted normal values at the screening visit. * a documented positive response to the reversibility test at the screening visit, defined as δfev1 ≥ 12% and ≥ 200 ml over baseline, 30 minutes after 400 μg salbutamol pmdi * patients free of long-acting beta2-agonists (labas) treatment for at least 2 weeks before the screening visit. * patients free of short-acting beta2-agonists (sabas) treatment for at least 6 hours before the screening visit. * non-smokers or ex-smokers exclusion criteria: * pregnant or lactating women or all women physiologically capable of becoming pregnant unless they are menopausal or are using effective and acceptable methods of contraception. * significant seasonal variation in asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitizer. * history of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in intensive care unit) within 1 year before screening. * occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening visit. * diagnosis of chronic obstructive pulmonary disease (copd) * history of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency. * diagnosis of restrictive lung disease. * patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12 weeks for parenteral depot corticosteroids) before screening visit. * intolerance or contra-indication to treatment with beta2-agonists and/or inhaled corticosteroids. * allergy, sensitivity or intolerance to study drugs or excipients. * significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality.